利伐沙班在肿瘤相关静脉血栓栓塞抗凝治疗中的研究进展

Advances in the study of Rivaroxaban in anticoagulant therapy of cancer-associated venous thromboembolism

肿瘤患者有着较高的静脉血栓栓塞(VTE)发生率,VTE也是肿瘤患者常见的致死原因,临床治疗指南强调药物抗凝是这类疾病的基础治疗。新型口服抗凝药物利伐沙班是一种可逆的直接因子Xa抑制剂,与传统抗凝药物华法林及低分子肝素(LMWH)相比,无需常规监测凝血指标,服用方便,且疗效与安全性已被大量循证医学证据和临床研究所证实。现对利伐沙班在肿瘤相关VTE抗凝治疗中的研究进展展开综述,为临床医生的个体化用药方案提供参考。

Cancer patients have a high incidence of venous thromboembolism(VTE),which is also a common cause of death in cancer patients.In the clinical treatment guidelines,the drug anticoagulation is emphasized as the primary treatment for such diseases.The new oral anticoagulant rivaroxaban is a reversible direct factor Xa inhibitor.Compared with the traditional anticoagulant drugs warfarin or low molecular weight heparin(LMWH),it does not require routine monitoring of coagulation indicators,which makes it convenient to administer.Moreover,its efficacy and safety have been validated by a large amount of evidence-based medical evidence and clinical studies.This article summarizes the development of the research of Rivaroxaban in the anticoagulant treatment of cancer-associated VTE and provides a reference for clinicians'individualized drug regimen.